Mikkael A Sekeres

Mikkael A Sekeres

UNVERIFIED PROFILE

Are you Mikkael A Sekeres?   Register this Author

Register author
Mikkael A Sekeres

Mikkael A Sekeres

Publications by authors named "Mikkael A Sekeres"

Are you Mikkael A Sekeres?   Register this Author

100Publications

2413Reads

33Profile Views

Impact of germline CTC1 alterations on telomere length in acquired bone marrow failure.

Br J Haematol 2019 Jun 19;185(5):935-939. Epub 2019 Mar 19.

Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.15862DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6536344PMC
June 2019

Rethinking clinical trial endpoints in myelodysplastic syndromes.

Leukemia 2019 03 30;33(3):570-575. Epub 2019 Jan 30.

Leukemia Programs, Cleveland Clinic Taussig Cancer Institute and Dana-Farber Cancer Institute, Cleveland, OH, and Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41375-018-0367-7DOI Listing
March 2019

Wilms tumor 1 expression: addressing the 'elephant' in MDS.

Leuk Lymphoma 2019 Mar 4;60(3):566-567. Epub 2019 Feb 4.

a Leukemia Program, Department of Hematology and Medical Oncology , Taussig Cancer Institute, Cleveland Clinic , Cleveland , OH , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2018.1516882DOI Listing
March 2019

Low clinical trial accrual of patients with myelodysplastic syndromes: Causes and potential solutions.

Cancer 2018 Dec 5;124(24):4601-4609. Epub 2018 Oct 5.

Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/cncr.31769
Publisher Site
http://dx.doi.org/10.1002/cncr.31769DOI Listing
December 2018

The role of hypomethylating agents prior to hematopoietic cell transplantation in myelodysplastic syndromes.

Best Pract Res Clin Haematol 2018 12 20;31(4):346-350. Epub 2018 Sep 20.

Hematology and Medical Oncology - Leukemia Program, Cleveland Clinic, 9500 Euclid Avenue, Desk CA-60, Cleveland, OH 44195, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.beha.2018.09.001DOI Listing
December 2018

Therapeutic outcomes using subcutaneous low dose alemtuzumab for acquired bone marrow failure conditions.

Br J Haematol 2018 Oct 14;183(1):133-136. Epub 2017 Sep 14.

Department of Translational Hematology and Oncology, Taussig Cancer Institute, Cleveland, OH, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.14907DOI Listing
October 2018

Clinical Outcomes With Ring Sideroblasts and SF3B1 Mutations in Myelodysplastic Syndromes: MDS Clinical Research Consortium Analysis.

Clin Lymphoma Myeloma Leuk 2018 08 26;18(8):528-532. Epub 2018 May 26.

Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2018.05.016DOI Listing
August 2018

New drugs in AML: uses and abuses.

Leukemia 2018 07 6;32(7):1479-1481. Epub 2018 Jun 6.

Leukemia Program, Cleveland Clinic, Cleveland, OH, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41375-018-0168-zDOI Listing
July 2018

Risk of Hematologic Malignancies After Radioiodine Treatment of Well-Differentiated Thyroid Cancer.

J Clin Oncol 2018 Jun 18;36(18):1831-1839. Epub 2017 Dec 18.

Remco J. Molenaar, Surbhi Sidana, Tomas Radivoyevitch, Anjali S. Advani, Aaron T. Gerds, Hetty E. Carraway, Dana Angelini, Matt Kalaycio, Aziz Nazha, David J. Adelstein, Christian Nasr, Jaroslaw P. Maciejewski, Navneet S. Majhail, Mikkael A. Sekeres, and Sudipto Mukherjee, Cleveland Clinic, Cleveland, OH; Remco J. Molenaar, University of Amsterdam, Amsterdam, the Netherlands; and Surbhi Sidana, Mayo Clinic, Rochester, MN.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.75.0232DOI Listing
June 2018

Reply to A. Piccardo et al, E. Hindié et al, M.C. Kreissl et al, M. Doss, J. Buscombe, R. Fisher, M. Sollini et al, M. Lichtenstein, and M. Tulchinsky et al.

J Clin Oncol 2018 Jun 3;36(18):1889-1892. Epub 2018 May 3.

Remco J. Molenaar, Cleveland Clinic, Cleveland, Ohio, and University of Amsterdam, Amsterdam, the Netherlands; Surbhi Sidana, Cleveland Clinic, Cleveland, Ohio, and Mayo Clinic, Rochester, MN; and Tomas Radivoyevitch, Aaron T. Gerds, Hetty E. Carraway, Matt Kalaycio, Aziz Nazha, David J. Adelstein, Christian Nasr, Jaroslaw P. Maciejewski, Navneed S. Majhail, Mikkael A. Sekeres, and Sudipto Mukherjee, Cleveland Clinic, Cleveland, Ohio.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2018.78.4074
Publisher Site
http://dx.doi.org/10.1200/JCO.2018.78.4074DOI Listing
June 2018

Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.

N Engl J Med 2018 Jun 2;378(25):2386-2398. Epub 2018 Jun 2.

From the University of Texas M.D. Anderson Cancer Center, Houston (C.D.D., H.M.K.); Memorial Sloan Kettering Cancer Center (E.M.S., M.S.T.) and Weill Cornell Medical College (G.J.R.), New York; Institut Gustave Roussy, Villejuif (S.B., C.W.), and Centre Hospitalier Universitaire Bordeaux, Bordeaux (A.P.) - both in France; Northwestern University, Chicago (J.K.A.); Ohio State University Wexner Medical Center, Columbus (A.S.M.); Sylvester Comprehensive Cancer Center, University of Miami, Miami (R.S.); University of Texas Southwestern Medical Center, Dallas (R.H.C.); University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco (G.N.M.), and City of Hope Medical Center, Duarte (A.S.S.) - both in California; University of Colorado School of Medicine, Aurora (D.A.P.); Sarah Cannon Research Institute, Nashville (W.D.); Massachusetts General Hospital Cancer Center (A.T.F.) and Dana-Farber Cancer Institute (R.M.S.), Boston, and Agios Pharmaceuticals, Cambridge (S.C., H.W., V.Z., K.E.Y., S.M.K., H.Y., D.D., B.F., M.G., H.L., S.A., B.W., E.C.A.) - all in Massachusetts; University of Alabama at Birmingham, Birmingham (H.P.E.); Johns Hopkins University, Baltimore (G.T.P.); Washington University School of Medicine, St. Louis (G.L.U.); Mayo Clinic, Jacksonville, FL (J.M.F.); Oregon Health and Science University Knight Cancer Institute, Portland (E.T.); Hollings Cancer Center, Medical University of South Carolina, Charleston (R.K.S.); Winship Cancer Institute of Emory University, Atlanta (M.L.A.); Mayo Clinic, Phoenix, AZ (J.L.S.); and Cleveland Clinic, Cleveland (M.A.S.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1716984DOI Listing
June 2018

Denial's Many Faces.

J Clin Oncol 2018 May 22;36(13):1374-1375. Epub 2018 Feb 22.

All authors: Cleveland Clinic, Cleveland, OH.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.77.3275DOI Listing
May 2018

Strategies for success in creating an effective multihospital health-system pharmacy and therapeutics committee.

Am J Health Syst Pharm 2018 Apr;75(7):451-455

Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2146/ajhp170531DOI Listing
April 2018

Clinical features and treatment outcomes in large granular lymphocytic leukemia (LGLL).

Leuk Lymphoma 2018 02 20;59(2):416-422. Epub 2017 Jun 20.

a Department of Translational Hematology and Oncology Research , Taussig Cancer Institute, Cleveland Clinic , Cleveland , OH , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2017.1339880DOI Listing
February 2018

Fanconi Anemia germline variants as susceptibility factors in aplastic anemia, MDS and AML.

Oncotarget 2018 Jan 16;9(2):2050-2057. Epub 2017 Dec 16.

Department of Translational Hematology and Oncology Research, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.23328DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5788620PMC
January 2018

Long-Term Outcomes of Hairy Cell Leukemia Treated With Purine Analogs: A Comparison With the General Population.

Clin Lymphoma Myeloma Leuk 2017 Dec 14;17(12):857-862. Epub 2017 Jul 14.

Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2017.07.003DOI Listing
December 2017

Prognostic models in predicting outcomes in myelodysplastic syndromes after hypomethylating agent failure.

Leuk Lymphoma 2017 11 28;58(11):2532-2539. Epub 2017 Mar 28.

a Leukemia Program, Department of Hematology and Medical Oncology , Taussig Cancer Institute, Cleveland Clinic , Cleveland , OH , USA.

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/10428194.2017.1
Publisher Site
http://dx.doi.org/10.1080/10428194.2017.1307361DOI Listing
November 2017

A call for action: Increasing enrollment of untreated patients with higher-risk myelodysplastic syndromes in first-line clinical trials.

Cancer 2017 Oct 31;123(19):3662-3672. Epub 2017 Jul 31.

Department of Hematology, Department of Internal Medicine, Yale Comprehensive Cancer Center, Yale University School of Medicine, New Haven, Connecticut.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.30903DOI Listing
October 2017

Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117.

J Clin Oncol 2017 Aug 9;35(24):2745-2753. Epub 2017 May 9.

Mikkael A. Sekeres and Aziz Nazha, Cleveland Clinic, Cleveland; Clara D. Bloomfield, The Ohio State University Comprehensive Cancer Center, Columbus, OH; Megan Othus and Anna Moseley, SWOG Statistical Center; Min Fang and Frederick R. Appelbaum, Fred Hutchinson Cancer Research Center, Seattle, WA; Alan F. List, H. Lee Moffitt Cancer Center, Tampa, FL; Olatoyosi Odenike, University of Chicago, Chicago; Mario R. Velasco, Heartland NCORP/Cancer Care Specialists of Central Illinois, Decatur, IL; Richard M. Stone, Dana Farber Cancer Institute; Eyal C. Attar, Massachusetts General Hospital, Boston, MA; Steven D. Gore, Yale University, New Haven, CT; Mark R. Litzow, Mayo Clinic, Rochester, MN; Rena Buckstein, Sunnybrook Health Sciences Centre, Toronto; Elina K. Cook, Alyssa H. Cull, and Michael J. Rauh, Queen's University, Kingston, Ontario, Canada; Diane Roulston, University of Michigan, Ann Arbor, MI; Yanming Zhang, Memorial Sloan-Kettering Cancer Center, New York, NY; Rakesh Gaur, Kansas City National Cancer Institute Community Oncology Research Program, Prairie Village, KS; Ehab Atallah, Medical College of Wisconsin, Milwaukee, WI; and Harry P. Erba, University of Alabama, Birmingham, AL.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.66.2510DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5562170PMC
August 2017

Optimizing the use of hypomethylating agents in myelodysplastic syndromes: Selecting the candidate, predicting the response, and enhancing the activity.

Semin Hematol 2017 07 23;54(3):147-153. Epub 2017 Jun 23.

Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminhematol.2017.06.001DOI Listing
July 2017

Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents.

J Clin Oncol 2017 May 28;35(14):1591-1597. Epub 2017 Mar 28.

Sophie Park, Centre Hospitalier Universitaire (CHU) Grenoble Alpes, Université Grenoble Alpes, Grenoble; Jean-François Hamel and Sylvain Thépot, CHU d'Angers; Sylvain Thépot, Université d'Angers, Institut National de la Santé et de la Recherche Médicale, Unité 1232, and LabEx IGO, Angers; Andrea Toma, CHU Henri Mondor, Assistance Publique Hôpitaux de Paris (AP-HP), Université Paris-Est Créteil; Rosa Sapena and Pierre Fenaux, CHU Saint Louis, AP-HP, Université Paris X; François Dreyfus, CHU Cochin, AP-HP, Université Paris V, Paris; Charikleia Kelaidi, CHU Avicenne, Avicenne; Odile Beyne-Rauzy, Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse; Aspasia Stamatoullas, Centre Henri Becquerel, Rouen; Agnès Guerci-Bresler, CHU Nancy, Nancy; Dominique Bordessoule, CHU Dupuytren, Limoges; Pascale Cony-Makhoul, Centre Hospitalier Annecy Genevois, Epagny Metz-Tessy; Stéphane Cheze, CHU de Caen, Caen; Eric Wattel, Centre Hospitalier Lyon-Sud, Pierre Bénite, Lyon; Christian Rose, Université Catholique de Lille, Lille; Norbert Vey, Institut Paoli-Calmettes Marseille, Marseille, France; Maria Diez Campelo, Hospital Universitario de Salamanca, Salamanca; Teresa Bernal, Hospital Central de Asturias, Oviedo; Fernando Ramos, Hospital de León, León; Marisa Calabuig, Hospital Clínico de Valencia; Guillermo F. Sanz, Hospital Universitario y Politecnico La Fe, Valencia, Spain; Valeria Santini and Alessandro Sanna, Azienda Ospedaliero Universitaria (AOU) Careggi and University of Florence, Florence; Enrico Balleari, Istituto di Ricovero e Cura a Carattere Scientifico AOU San Martino di Genova, Genova; Daniela Gioia, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, Alessandria; Dario Ferrero, Università degli Studi di Torino; Gianluca Gaidano, Amedeo Avogadro University of Eastern Piedmont, Torino; Giovanni Cametti, Ospedale Maggiore di Chieri, Chieri; Fabrizio Pane, Università Federico II, Napoli, Italy; Mikkael A. Sekeres and Jaime Fensterl, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; Rami Komrokji, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; David P. Steensma, Dana-Farber Cancer Institute, Boston, MA; Gail J. Roboz, Weill Medical College of Cornell University, New York, NY; Jennifer Kaivers and Ulrich Germing, University of Düsseldorf, Düsseldorf; Katharina Götze and Catharina Müller-Thomas, Universität München, München, Germany; and Ioannis Kotsianidis, Democritus University of Thrace, University Hospital of Alexandroupolis, Alexandroupolis, Greece.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.71.3271DOI Listing
May 2017

Precision Medicine in Myelodysplastic Syndromes and Leukemias: Lessons from Sequential Mutations.

Annu Rev Med 2017 01 7;68:127-137. Epub 2016 Sep 7.

Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio 44195; email:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1146/annurev-med-062915-095637DOI Listing
January 2017

Improving Prognostic Modeling in Myelodysplastic Syndromes.

Curr Hematol Malig Rep 2016 12;11(6):395-401

Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Desk R35 9500 Euclid Ave, Cleveland, OH, 44195, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11899-016-0342-1DOI Listing
December 2016

Managing patients with higher-risk myelodysplastic syndrome with stable disease on hypomethylating agents.

Leuk Lymphoma 2015 11;56(12):3267-9. Epub 2015 Sep 11.

a Cleveland Clinic , Cleveland , OH , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428194.2015.1063149DOI Listing
September 2016

Long Day's Journey Into Night for Lower-Risk Myelodysplastic Syndromes.

J Clin Oncol 2016 09 27;34(25):2956-7. Epub 2016 Jun 27.

Cleveland Clinic, Cleveland, OH

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.68.2492DOI Listing
September 2016

Myelodysplastic Syndromes: Going Gently Into That Good Night.

J Oncol Pract 2016 09;12(9):795-6

Cleveland Clinic, Cleveland, OH

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JOP.2016.015925
Publisher Site
http://dx.doi.org/10.1200/JOP.2016.015925DOI Listing
September 2016

Combination therapies for MDS and AML: Does one plus one equal one?

Leuk Lymphoma 2016 23;57(3):505-6. Epub 2015 Dec 23.

a Leukemia Program, Cleveland Clinic Taussig Cancer Institute , Cleveland , OH , USA.

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.3109/10428194.2015.1
Publisher Site
http://dx.doi.org/10.3109/10428194.2015.1102247DOI Listing
August 2016

Time, timing, and the treatment of diffuse large B-cell lymphoma.

Leuk Lymphoma 2016 Feb 5;57(2):247-248. Epub 2015 Oct 5.

a Leukemia Program, Cleveland Clinic Taussig Cancer Institute , Cleveland , OH , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428194.2015.1070155DOI Listing
February 2016

Myelodysplastic syndromes spatial clusters in disease etiology and outcome.

Leuk Lymphoma 2016 Feb 10;57(2):392-399. Epub 2015 Jul 10.

a Department of Population Health Science and Policy , Icahn School of Medicine at Mount Sinai , NY , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428194.2015.1071487DOI Listing
February 2016

Genomic patterns associated with hypoplastic compared to hyperplastic myelodysplastic syndromes.

Haematologica 2015 Nov 13;100(11):e434-7. Epub 2015 Aug 13.

Translational Hematology and Oncology Research Department, Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH, USA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2015.130112DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4825290PMC
November 2015

Molecular Testing in Myelodysplastic Syndromes for the Practicing Oncologist: Will the Progress Fulfill the Promise?

Oncologist 2015 Sep 20;20(9):1069-76. Epub 2015 Jul 20.

Section of Hematology, Department of Internal Medicine, Yale University and Yale Comprehensive Cancer Center, New Haven, Connecticut, USA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2015-0067DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4571815PMC
September 2015

The graceful exit or reluctant demise of the older adult with acute myeloid leukemia.

Cancer 2015 Aug 29;121(16):2678-80. Epub 2015 Apr 29.

Leukemia Program, The Cleveland Clinic, Cleveland, Ohio.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.29428DOI Listing
August 2015

Non-t(6;9) and Non-Inv(3) Balanced Chromosomal Rearrangements Are Associated With Poor Survival Outcomes in Myelodysplastic Syndromes.

Clin Lymphoma Myeloma Leuk 2015 Aug 2;15(8):489-95. Epub 2015 Apr 2.

Leukemia Program, Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH; Department of Translational Hematology and Oncology Research, Cleveland Clinic, Cleveland, OH. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2015.03.017DOI Listing
August 2015

In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs.

Authors:
Ayalew Tefferi Hagop Kantarjian S Vincent Rajkumar Lawrence H Baker Jan L Abkowitz John W Adamson Ranjana Hira Advani James Allison Karen H Antman Robert C Bast John M Bennett Edward J Benz Nancy Berliner Joseph Bertino Ravi Bhatia Smita Bhatia Deepa Bhojwani Charles D Blanke Clara D Bloomfield Linda Bosserman Hal E Broxmeyer John C Byrd Fernando Cabanillas George Peter Canellos Bruce A Chabner Asher Chanan-Khan Bruce Cheson Bayard Clarkson Susan L Cohn Gerardo Colon-Otero Jorge Cortes Steven Coutre Massimo Cristofanilli Walter J Curran George Q Daley Daniel J DeAngelo H Joachim Deeg Lawrence H Einhorn Harry P Erba Francisco J Esteva Elihu Estey Isaiah J Fidler James Foran Stephen Forman Emil Freireich Charles Fuchs James N George Morie A Gertz Sergio Giralt Harvey Golomb Peter Greenberg Jordan Gutterman Robert I Handin Samuel Hellman Paulo Marcelo Hoff Ronald Hoffman Waun Ki Hong Mary Horowitz Gabriel N Hortobagyi Clifford Hudis Jean Pierre Issa Bruce Evan Johnson Philip W Kantoff Kenneth Kaushansky David Khayat Fadlo R Khuri Thomas J Kipps Margaret Kripke Robert A Kyle Richard A Larson Theodore S Lawrence Ross Levine Michael P Link Scott M Lippman Sagar Lonial Gary H Lyman Maurie Markman John Mendelsohn Neal J Meropol Yoav Messinger Therese M Mulvey Susan O'Brien Roman Perez-Soler Raphael Pollock Josef Prchal Oliver Press Jerald Radich Kanti Rai Saul A Rosenberg Jacob M Rowe Hope Rugo Carolyn D Runowicz Brenda M Sandmaier Alan Saven Andrew I Schafer Charles Schiffer Mikkael A Sekeres Richard T Silver Lillian L Siu David P Steensma F Marc Stewart Wendy Stock Richard Stone Rainer Storb Louise C Strong Martin S Tallman Michael Thompson Naoto T Ueno Richard A Van Etten Julie M Vose Peter H Wiernik Eric P Winer Anas Younes Andrew D Zelenetz Charles A LeMaistre

Mayo Clin Proc 2015 Aug 23;90(8):996-1000. Epub 2015 Jul 23.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.mayocp.2015.06.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5365030PMC
August 2015

Mitigating Fear and Loathing in Managing Acute Myeloid Leukemia.

Semin Hematol 2015 Jul 17;52(3):249-55. Epub 2015 Mar 17.

Leukemia Program, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00371963150003
Publisher Site
http://dx.doi.org/10.1053/j.seminhematol.2015.03.009DOI Listing
July 2015

Treating myelodysplastic syndromes: is more better?

Lancet Haematol 2015 Jan 22;2(1):e2-3. Epub 2014 Dec 22.

Leukaemia program, Cleveland Clinic, Cleveland, OH, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2352-3026(14)00036-2DOI Listing
January 2015